טוען...
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin
Despite the clinical success of platinum-containing drugs in the treatment of solid tumors, acquired resistance remains a major obstacle. We previously identified a group of novel transplanaramine or transplatinum compounds based on distinct activity profiles in the NCI-60 panel. In the present stud...
שמור ב:
Main Authors: | , , , , , |
---|---|
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
Landes Bioscience
2012
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3679288/ https://ncbi.nlm.nih.gov/pubmed/22333583 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cc.11.5.19447 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|